Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
172 hedge funds and large institutions have $3.23B invested in Spark Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 50 reducing their positions, and 18 closing their positions.
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
28% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 50
26% more capital invested
Capital invested by funds: $2.57B → $3.23B (+$669M)
6% more funds holding
Funds holding: 162 → 172 (+10)
36% less call options, than puts
Call options by funds: $13.5M | Put options by funds: $21.3M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$68.9M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$24.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$21.1M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$18.5M |
| 5 |
BlackRock
New York
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$67.7M |
| 2 |
Janus Henderson Group
London,
|
-$23.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$21.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.5M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$18M |
ONCE Hedge Fund Activity: Q2 2018 in Review
172 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q2 2018, worth a combined $3.23B — up 26% from $2.57B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ONCE positions and 18 closed out — a net gain of 10 holders — while 64 added to existing stakes and 50 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $68.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $67.7M.
- 172 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q2 2018, up from 162 in Q1 2018.
- Funds reported $3.23B of Spark Therapeutics, Inc. Common Stock stock for Q2 2018, up 26% quarter-over-quarter.
- 28 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q2 2018 and 18 closed out, a net change of +10 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q2 2018 was Lord, Abbett & Co, an estimated $68.9M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q2 2018 was T. Rowe Price Associates, an estimated $67.7M sold.
Based on aggregated 13F filings for Q2 2018.